Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Trial end date:
2016-10-10
Target enrollment:
Participant gender:
Summary
This study consisted of a two year dose blinded phase during which patients received one of
five doses of siponimod (10, 2, 1.25, 0.5 or 0.25mg) following which patients were switched
to open label treatment with siponimod 2mg for approximately a further 3 years. It will
provide data on long term safety, tolerability and efficacy of siponimod in the RRMS patient
population